Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Immuno-Oncology, and Beyond.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TGFB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Active) | TGFB1 Recombinant Protein (Active Form) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View TGFB1 Products |
| Antigen (Latent) | Latent TGFB1 Complex (LAP-associated) Properly folded pro-form for activation mechanism studies. |
View TGFB1 Products |
| Gene Delivery | TGFB1 Premade Lentivirus (ORF) Full-length ORF for stable overexpression in fibroblast or immune cell lines. |
View TGFB1 Products |
| Benchmark Ab | Anti-TGFB1 Neutralizing Antibody (Fresolimumab Biosimilar) Recombinant positive control for blocking assays. |
View TGFB1 Products |
| Validator | TGFB1 siRNA Set For specific knockdown and isoform verification. |
View TGFB1 Products |
| Related Target: TGFB2 | TGFB2 Protein Isoform for selectivity screening (pan-TGFβ vs TGFB1-specific). |
View TGFB2 Products |
| Related Target: TGFB3 | TGFB3 Protein Third isoform for comprehensive off-target profiling. |
View TGFB3 Products |
| Related Target: TGFBR1 | TGFBR1 (ALK5) Kinase Domain Protein Downstream target for small molecule inhibitor studies. |
View TGFBR1 Products |
| Related Target: TGFBR2 | TGFBR2 Co-receptor essential for signaling complex. | View TGFBR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (TGFB1 vs TGFB2/3) | Human TGFB1, TGFB2, TGFB3 proteins available as homolog panel; Sequence verified by Mass Spec. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cynomolgus TGFB1 ortholog proteins with >95% purity; Endotoxin controlled. |
| Latent vs Active Conformation | Both LAP-associated (Latent) and mature active form proteins available; Disulfide bond verified. |
| SMAD Reporter Assay Standardization | High-activity TGFB1 protein batch-validated for luciferase reporter EC50 consistency. |
| Pan-TGFβ Trap Mechanism | TGFB1/TGFB2/TGFB3 triple protein bundle for affinity ranking. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live TGFB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TGFB1 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum mAbs and pan-neutralizing antibodies to context-dependent inhibitors, bifunctional fusion proteins (PD-L1/TGFβ traps), and isoform-selective approaches. As first-generation pan-TGFβ therapies face tolerability challenges in fibrosis indications, the next wave of R&D is targeting latent complex-specific activation blockers and tumor-microenvironment restricted delivery systems to circumvent systemic toxicity. The move towards more precise modulation reflects the narrow therapeutic window of TGFB1 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing/Monoclonal Antibody | Scholar Rock, Sanofi (Fresolimumab), Novartis (NIS793) | IPF, Solid Tumors, SMA | Selectivity Assay: Active vs Latent form binding; Conformational specificity. |
| Bispecific/Bifunctional Trap | Merck KGaA, 恒瑞 (SHR-1701), GSK (bintrafusp alfa) | Solid Tumors, NSCLC, Gastric Cancer | Heterodimer Validation & simultaneous PD-L1/TGFB1 binding; need high-purity dual antigens. |
| Antisense Oligo | BioNTech (BNT191) | Systemic Sclerosis | Knockdown efficiency validation; need TGFB1-specific siRNA controls. |
| Small Molecule (Receptor) | Novartis, Eli Lilly, Scripps Research (galunisertib derivatives) | Oncology | Kinase assays (mutant vs WT proteins); ALK5 selectivity; need TGFBR1 protein. |